Publications

Browse Publications:

By Category:

• Abstract Posters (8)
• Research Papers (134)
• Presentations (6)

By Physician:

• David Charytan, MD (9)
• Donald E. Cutlip, MD (76)
• Ralph D'Agostino, PhD (15)
• Elazer R. Edelman, MD, PhD (5)
• Maurizio Fava, MD (5)
• Lawrence Garcia, MD (0)
• Ernest V. Gervino, Sc.D., FACSM (1)
• Michael Gibson, MD (4)
• Kalon K.L. Ho, MD, MSc (21)
• Michael Jaff, MD (0)
• Mark Josephson, MD (11)
• Joseph Massaro, PhD (18)
• Laura Mauri, MD (35)
• Andrew Nierenberg, MD (0)
• Mark H. Pollack, MD (1)
• Jeffrey J. Popma, MD (46)
• Matthew R. Reynolds, M.D, M.Sc. (18)
• Alexei Shvilkin, MD, PhD (14)
• Peter Zimetbaum, MD (30)

Publications From: Laura Mauri, MD

Late Loss Versus Target Lesion Revascularization: What Is the Difference in the Numbers?

Long-Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts

Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv. 2009 Oct;2(10):967-76.

Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv. 2009 Oct;2(10):977-85.

In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT...registry. JACC Cardiovasc Interv. 2009 Aug;2(8):767-75.

Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. JACC Cardiovasc Interv. 2009 Jun;2(6):498-503.

A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. JACC Cardiovasc Interv. 2009 Feb;2(2):91-6.

Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int. 2009 Jan;75(1):80-7.

Drug-Eluting or Bare-Metal Stenting in Patients With Diabetes Mellitus. Results From the Massachusetts Data Analysis Center Registry. Circulation. 2008 Nov 25;118(22):2277-85, 7p following 2285.

Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008 Oct 28;118(18):1817-27.

Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008 Sep 25;359(13):1330-42.

Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int. 2008 Sep 24.

3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. JACC Cardiovasc Interv. 2008 Aug;1(4):439-48.

A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. JACC Cardiovasc Interv. 2008 Jun;1(3):248-57.

Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol. 2008 May 13;51(19):1844-53.

Studies of Drug-Eluting Stents: To Each His Own? Circulation 2008 Apr 22;117(16):2047-50.

Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart. 2008 Mar;94(3):322-8.

Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008 Feb 12;117(6):790-7.

The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. Curr Opin Cardiol. 2007 Nov;22(6):565-571.

The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol. 2007 Oct 9;50(15):1442-9.

Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007 Oct 2;50(14):1299-304.

Impact of Late Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation on 4-Year Clinical Events. Intravascular Ultrasound Analysis from the Multicenter, Randomized, RAVEL, E-SIRIUS and SIRIUS Trials.Heart. 2007 Aug 29; [Epub ahead of print]

Carotid artery stenting with emboli protection surveillance study: thirty-day results of the CASES-PMS study. Catheter Cardiovasc Interv. 2007 Aug 1;70(2):316-23.

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.

Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9.

Devices for Distal Protection During Percutaneous Coronary Revascularization. Circulation 2006; 113;2651-2656

Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7.

The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J. 2006 Sep;152(3):558-64.

Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped? Curr Cardiol Rep. 2006 Jul;8(4):267-71.

Drug-Eluting Stenting for Unprotected Left Main Coronary Artery Disease. JACC February 21, 2006:878-81.

Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation. 2005 Nov 1;112(18):2833-9.

Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison.Circulation. 2005 Jun 28;111(25):3435-42.

Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol. 2005 May 15;95(10):1140-5.

Surrogates, Substudies, and Real Clinical End Points in Trials of Drug-Eluting Stents. JACC April 19, 2005:1206-12.

Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002 Nov 15;90(10):1079-83.

Meet The HCRI Team

Theodora Cohen, PhD

Senior Director of Biostatistics & Data Management

Since 2005, Dr. Theodora Cohen has been managing HCRI's growing Biostatistics and clinical trial support business. Previously, she…

Submit an RFP

Quick Links

• Contact HCRI
• Careers at HCRI
• Information for Patients

930-W Commonwealth Avenue
Boston MA 02215
t: 617.632.1515    f: 617.632.1580

©2009 Harvard Clinical Research Institute